SCHEMBL30837867

SCHEMBL30837867

COc1cccc(-c2ccc(Cn3c(=O)c4cc(OC(CF)CF)c(F)cc4n(C4CCN(C=O)CC4)c3=O)cn2)c1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 9/20 0.58
▸ PDE7B Q9NP56 4/20 0.58
▸ PDE8A O60658 3/20 0.58
▸ GNRHR P30968 3/20 0.39
▸ OPRM1 P35372 2/20 0.37
▸ OPRL1 P41146 2/20 0.37
▸ PRKDC P78527 1/20 0.36
▸ PIK3CA P42336 3/20 0.36
▸ MTOR P42345 3/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL100928 1.00 PDE7A (0.58) PDE7APDE7BPDE8AGNRHROPRM1
SCHEMBL100395 0.93 PDE7A (0.62) PDE7APDE7BPDE8AOPRM1OPRL1
SCHEMBL30837936 0.93 PDE7A (0.62) PDE7APDE7BPDE8AOPRM1OPRL1
SCHEMBL101167 0.92 PDE7A (0.53) PDE7APDE7BPDE8AMAPT
SCHEMBL173205 0.91 PDE7A (0.52) PDE7APDE7BPDE8AOPRM1OPRL1
SCHEMBL101005 0.89 PDE7A (0.56) PDE7APDE7BPDE8ACYP3A4TP53
SCHEMBL100993 0.88 PDE7A (0.55) PDE7APDE7BPDE8A
SCHEMBL101250 0.88 PDE7A (0.66) PDE7APDE7BPDE8AGNRHROPRM1
SCHEMBL100103 0.87 PDE7A (0.55) PDE7APDE7BPDE8AOPRM1OPRL1
SCHEMBL100396 0.85 PDE7A (0.53) PDE7APDE7BPDE8AOPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 — — EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 — — WO disclosed
Send feedback